Nicola E. Wilsher

1.3k total citations
20 papers, 742 citations indexed

About

Nicola E. Wilsher is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Organic Chemistry. According to data from OpenAlex, Nicola E. Wilsher has authored 20 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 4 papers in Pathology and Forensic Medicine and 3 papers in Organic Chemistry. Recurrent topics in Nicola E. Wilsher's work include Synthesis and biological activity (3 papers), Tea Polyphenols and Effects (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Nicola E. Wilsher is often cited by papers focused on Synthesis and biological activity (3 papers), Tea Polyphenols and Effects (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Nicola E. Wilsher collaborates with scholars based in United Kingdom and Greece. Nicola E. Wilsher's co-authors include Randolph Arroo, Vasilis P. Androutsopoulos, Ketan C. Ruparelia, Gerry A. Potter, Gerard A. Potter, David J. Boocock, Donald J. L. Jones, P.B. Farmer, W P Steward and Andreas J. Gescher and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.

In The Last Decade

Nicola E. Wilsher

19 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicola E. Wilsher United Kingdom 13 421 160 120 104 74 20 742
Renata Mikstacka Poland 15 321 0.8× 196 1.2× 182 1.5× 78 0.8× 70 0.9× 21 726
Stewart Sale United Kingdom 11 469 1.1× 187 1.2× 90 0.8× 117 1.1× 120 1.6× 16 839
Monique Quesne France 6 355 0.8× 180 1.1× 56 0.5× 102 1.0× 63 0.9× 8 775
Joanna Jakubowicz-Gil Poland 21 564 1.3× 45 0.3× 145 1.2× 134 1.3× 94 1.3× 55 1.1k
Shiby Paul United States 11 297 0.7× 147 0.9× 134 1.1× 145 1.4× 151 2.0× 14 730
Angelo Pugliese United States 16 586 1.4× 57 0.4× 181 1.5× 145 1.4× 124 1.7× 23 1.1k
Karin Pleban Austria 9 219 0.5× 141 0.9× 135 1.1× 200 1.9× 27 0.4× 10 555
Ikuo Miyahisa Japan 13 628 1.5× 47 0.3× 102 0.8× 60 0.6× 53 0.7× 20 813
Norbert Handler Austria 14 430 1.0× 473 3.0× 243 2.0× 88 0.8× 143 1.9× 34 1.0k

Countries citing papers authored by Nicola E. Wilsher

Since Specialization
Citations

This map shows the geographic impact of Nicola E. Wilsher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola E. Wilsher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola E. Wilsher more than expected).

Fields of papers citing papers by Nicola E. Wilsher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola E. Wilsher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola E. Wilsher. The network helps show where Nicola E. Wilsher may publish in the future.

Co-authorship network of co-authors of Nicola E. Wilsher

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola E. Wilsher. A scholar is included among the top collaborators of Nicola E. Wilsher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola E. Wilsher. Nicola E. Wilsher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruparelia, Ketan C., Keti Zeka, Nicola E. Wilsher, et al.. (2024). CYP1-Activation and Anticancer Properties of Synthetic Methoxylated Resveratrol Analogues. Molecules. 29(2). 423–423. 2 indexed citations
2.
3.
Wilsher, Nicola E., et al.. (2022). A validated liquid chromatography‐tandem mass spectroscopy method for the quantification of tolinapant in human plasma. SHILAP Revista de lepidopterología. 3(5-6). 198–204. 1 indexed citations
4.
Hindley, Christopher J., Lynsey Fazal, Joanne M. Munck, et al.. (2020). Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models. Blood. 136(Supplement 1). 7–8. 1 indexed citations
5.
Ruparelia, Ketan C., et al.. (2019). The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells. Bioorganic & Medicinal Chemistry Letters. 29(11). 1403–1406. 5 indexed citations
6.
Ward, George A., Edward J. Lewis, Jong Sook Ahn, et al.. (2018). ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Molecular Cancer Therapeutics. 17(7). 1381–1391. 53 indexed citations
7.
Ruparelia, Ketan C., Keti Zeka, Nicola E. Wilsher, et al.. (2018). The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells. Medicinal Chemistry. 14(4). 322–332. 12 indexed citations
8.
Tamanini, Emiliano, Ildiko M. Buck, Gianni Chessari, et al.. (2017). Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP). Journal of Medicinal Chemistry. 60(11). 4611–4625. 57 indexed citations
9.
Wilsher, Nicola E., Randolph Arroo, Minos–Timotheos Matsoukas, et al.. (2017). Cytochrome P450 CYP1 metabolism of hydroxylated flavones and flavonols: Selective bioactivation of luteolin in breast cancer cells. Food and Chemical Toxicology. 110. 383–394. 52 indexed citations
10.
Chessari, Gianni, Ildiko M. Buck, James E. H. Day, et al.. (2015). Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. Journal of Medicinal Chemistry. 58(16). 6574–6588. 67 indexed citations
11.
Arroo, Randolph, Vasilis P. Androutsopoulos, Ketan C. Ruparelia, et al.. (2009). Phytoestrogens as natural prodrugs in cancer prevention: dietary flavonoids. Phytochemistry Reviews. 8(2). 375–386. 33 indexed citations
12.
Androutsopoulos, Vasilis P., Nicola E. Wilsher, Randolph Arroo, & Gerry A. Potter. (2008). Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Letters. 274(1). 54–60. 74 indexed citations
13.
Arroo, Randolph, et al.. (2008). Phytoestrogens as natural prodrugs in cancer prevention: a novel concept. Phytochemistry Reviews. 7(3). 431–443. 18 indexed citations
14.
Chan, Florence, Chongbo Sun, Meg Perumal, et al.. (2007). Characterization of CCT129202, a novel Aurora kinase inhibitor and in vivo quantification of biological activity. 6. 1 indexed citations
15.
16.
Chan, Florence, Chongbo Sun, Meg Perumal, et al.. (2007). Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Molecular Cancer Therapeutics. 6(12). 3147–3157. 55 indexed citations
17.
Asad, Yasmin J., et al.. (2006). A validated liquid chromatographic–tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma. Journal of Chromatography B. 843(2). 262–267. 24 indexed citations
18.
Honess, Davina J., et al.. (2005). Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy. Cancer Research. 65. 930–931. 1 indexed citations
19.
Verschoyle, Richard D., David J. Boocock, Donald J. L. Jones, et al.. (2004). Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. British Journal of Cancer. 90(3). 736–744. 225 indexed citations
20.
Collis, Alan, Martyn Foster, Frank Halley, et al.. (2001). RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorganic & Medicinal Chemistry Letters. 11(5). 693–696. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renata Mikstacka Breakdown of academic impact, for papers by Stewart Sale Breakdown of academic impact, for papers by Monique Quesne Breakdown of academic impact, for papers by Joanna Jakubowicz-Gil Breakdown of academic impact, for papers by Shiby Paul Breakdown of academic impact, for papers by Angelo Pugliese Breakdown of academic impact, for papers by Karin Pleban Breakdown of academic impact, for papers by Ikuo Miyahisa Breakdown of academic impact, for papers by Norbert Handler
Rankless by CCL
2026